FDA CDER 发布 MAPP 5100.7《良好审评规范与程序:NDA 与 BLA 的临床药理学审评》
FDA发布《良好审评规范程序:新药申请与生物制品许可申请的临床药理学审评》
FDA 药物评价与研究中心(CDER)于2026年11月10日发布 MAPP 5100.7,为临床药理学办公室审评 NDA 与 BLA 建立良好审评规范,自发布之日起生效。
2026年11月10日,FDA 药物评价与研究中心(CDER)发布了 MAPP 5100.7《良好审评规范与程序:新药申请(NDA)与生物制品许可申请(BLA)的临床药理学审评》。
这是一份 18 页的政策手册,OCP 第一次把“临床药理审评该怎么做”写成成文的手册,包含谁来审、按什么问题审、审完写成什么样、内部意见不一致时如何处理等。
里面最值得记住的是四个问题。每一项 NDA/BLA 的临床药理审评,都要回答:现有临床药理学信息在多大程度上构成有效性证据;拟用剂量对目标人群是否合适;基于内在因素,亚人群是否需要替代剂量或管理策略;是否存在有临床意义的食物-药物或药物-药物相互作用,以及应如何管理。
另一处值得留意的是“分歧怎么处理”:审评组内部出现无法解决的重大分歧、签署人不同意审评组最终建议、OCP 要采取有先例意义或有争议的立场时,必须单独撰写一份签署人备忘录,把不同意见留在监管档案里。
以下为全文对照,含附件 1 的审评模板与各章节写作要求。
Document / 文件
MAPP 5100.7(Manual of Policies and Procedures)
Title / 标题
Good Review Practices and Procedures: Clinical Pharmacology Review of New Drug Applications (NDAs) and Biologics License Applications (BLAs)
Originating Office / 起草部门
Office of Translational Sciences(转化科学办公室)→ Office of Clinical Pharmacology(临床药理学办公室)
Effective Date / 生效日期
2026年11月10日(发布之日起生效)
Length / 篇幅
18页(正文7页+附件1共11页)
Revision / 修订
Initial(初版,此前无修订记录)
PURPOSE
目的
This Manual of Policies and Procedures (MAPP) establishes good review practices (GRPs) for the reviews of new drug applications (NDAs) and biologics license applications (BLAs) in the Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER). In general, the principles outlined herein may also be applicable to other submissions, as appropriate.
本《政策与程序手册》(MAPP)为药物评价与研究中心(CDER)转化科学办公室(OTS)临床药理学办公室(OCP)对 New Drug Application(NDA,新药申请)与 Biologics License Application(BLA,生物制品许可申请)的审评,确立良好审评规范(GRP)。一般而言,本文所述原则在适当情况下也可适用于其他类型的申报。
This MAPP describes OCP's integrated review procedure to evaluate NDAs and BLAs.
本 MAPP 描述 OCP 用于评价 NDA 与 BLA 的综合审评程序。
The GRPs and procedures described apply for all templates used to document the review.
所述良好审评规范与程序,适用于记录审评所用的全部模板。
BACKGROUND
背景
Clinical pharmacology is a multidisciplinary science. OCP reviews of NDAs and BLAs are expected to synthesize information from all relevant clinical pharmacology knowledge areas, including drug disposition, pharmacology, biomarkers, quantitative methods, drug safety, pharmacotherapy, and clinical trial methods to inform regulatory decisions (e.g., approvability, labeling, and postmarketing requirements (PMRs) or section 506B of the Federal Food, Drug, and Cosmetic Act postmarketing commitments (PMCs)). For each NDA or BLA submission, staff from various OCP units (divisions, groups, etc.) with expertise in relevant knowledge areas create a review team.1 Once the review team is formed, team members work collaboratively within and outside of OCP to do the following:
临床药理学是一门多学科科学。OCP 对 NDA 与 BLA 的审评,要求综合全部相关临床药理学知识领域的信息——包括药物体内处置、药理学、生物标志物、定量方法、药物安全性、药物治疗学与临床试验方法——为监管决定(例如可否批准、说明书、以及上市后要求(PMR)或《联邦食品、药品和化妆品法》第 506B 条项下的上市后承诺(PMC))提供依据。对每一项 NDA 或 BLA 申报,由 OCP 各单元(处、组等)中具备相关知识领域专长的人员组成审评组。审评组组建后,成员在 OCP 内外协作完成以下工作:
· Identify issues that are important for the review of the application and subsequent regulatory action (including decisions on whether the application can be filed as well as key review questions)
· 识别对申报审评及后续监管行动重要的问题(包括能否受理的决定,以及关键审评问题)。
· Assess information in the application along with previously established knowledge to address issues regarding dosage selection and optimization, therapeutic individualization, and benefit/risk balance
· 结合申报资料中的信息与既有知识,评估剂量选择与优化、治疗个体化以及获益/风险平衡方面的问题。
· Identify any critical gaps hindering the optimization of therapeutic use and recommend studies that can practically address those gaps
· 识别妨碍治疗使用优化的关键缺口,并建议可切实弥补这些缺口的研究。
· Provide labeling recommendations for the safe and effective use of the drug or biological product by the health care provider as per regulations and current FDA guidance
· 按法规与现行 FDA 指南,就医务人员安全有效使用该药品或生物制品提出说明书建议。
· Determine if any PMRs and/or PMCs will be established
· 确定是否需要设立 PMR 和/或 PMC。
· Provide recommendations informed by current scientific thinking and guided by established regulatory policies and practices
· 在现行监管政策与实践的框架下,提出有当前科学认识支撑的建议。
This MAPP contains:
本 MAPP 包括:
· Guiding principles for conducting and documenting OCP reviews
· 开展并记录 OCP 审评的指导原则。
· Guiding questions for OCP reviews
· OCP 审评的指导性问题。
· GRP within OCP
· OCP 内部的良好审评规范。
1 见 OCP 网站(2026年9月22日访问):https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/office-clinical-pharmacology
POLICY
政策
The OCP review is based on the following guiding principles:
OCP 的审评基于以下指导原则:
· Review recommendations and decisions will be clinically relevant, pragmatic, and take into consideration the specific therapeutic context (e.g., nature of disease, size of population, unmet medical need, available treatments). Reviewers will utilize a risk-based approach that incorporates the totality of evidence.
· 审评建议与决定应具有临床相关性、切合实际,并考虑具体治疗背景(例如疾病性质、人群规模、未被满足的医疗需求、可及的治疗手段)。审评人员应采用基于风险的方法,纳入全部证据。
The following four guiding review questions are important to inform the safe and effective use of all drugs in the general indicated population as well as in specific populations. These questions will be addressed during the clinical pharmacology review (refer to Attachment 1 for more details on the content expected in the response for each of these questions):
以下四个指导性审评问题,对说明所有药品在通用适应证人群及特定人群中安全有效使用十分重要。这些问题应在临床药理学审评中予以回答(每个问题应答内容的要求,详见附件 1):
1. To what extent does the available clinical pharmacology information provide evidence of effectiveness?
1. 现有临床药理学信息在多大程度上构成有效性证据?
2. Is the proposed dosage appropriate for the general patient population for which the indication is being sought?
2. 拟用剂量对申请适应证所针对的通用患者人群是否合适?
3. Is an alternative dosage and/or management strategy required for subpopulations based on intrinsic factors?
3. 基于内在因素,亚人群是否需要替代剂量和/或管理策略?
4. Are there clinically relevant food-drug or drug-drug interactions, and what are the appropriate management strategies?
4. 是否存在有临床意义的食物-药物或药物-药物相互作用?适当的管理策略是什么?
· Reviewers from different units in OCP with the expertise needed for the particular NDA or BLA submission will work collaboratively to review the submission and incorporate feedback.
· 就具体 NDA 或 BLA 申报具备相应专长的 OCP 各单元审评人员,应协作审评并吸纳反馈。
· Reviewers will use the most current scientific and regulatory information available to ensure the highest quality reviews.
· 审评人员应使用可获取的最新科学与监管信息,以确保审评质量。
· Equal voice principles as outlined in MAPP 4151.8 Rev.2 will be employed for collaborative review and regulatory decision-making.
· 协作审评与监管决策采用 MAPP 4151.8 Rev.2 规定的“平等发言”(equal voice)原则。
The following describe documentation principles:
以下为记录原则:
· The OCP review team will use the review templates that are agreed upon by the CDER review team.
· OCP 审评组应使用经 CDER 审评组认可的审评模板。
· Important findings and recommended regulatory actions will be clearly and succinctly communicated in reviews. The review will logically guide the reader through the thought process used to identify and address scientific, clinical, and regulatory questions and issues.
· 重要发现与建议的监管行动,应在审评中清晰、简洁地表达。审评应以合乎逻辑的方式,引导读者走完识别并解决科学、临床与监管问题的思维过程。
ROLES AND RESPONSIBILITIES
角色与职责
All OCP Review Team Members:
OCP 审评组全体成员:
· All members of the OCP review team will work collaboratively and are jointly responsible for the stated OCP positions and recommendations.
· OCP 审评组全体成员应协作工作,并对 OCP 所表述的立场与建议共同负责。
· Review team members must participate in the following three ways to be listed as signatories:
· 审评组成员须以下列三种方式参与,方可列为签署人:
○ Contribute to the formulation and/or design of the review questions, approach to addressing the review questions, and/or the analysis and interpretation of the data.
○ 对审评问题的提出和/或设计、解决问题的思路,以及数据的分析与解读作出贡献。
○ Draft the review or critically revised it for important content.
○ 起草审评,或就重要内容作出实质性修改。
○ Approve the final version of the review to be entered into the regulatory record.
○ 批准进入监管档案的审评最终版本。
· Review teams consist of staff from various units in OCP, depending on the type of knowledge needed for the review. These areas may include drug- and disease-related clinical pharmacology, pharmacometrics, genomics and other biomarkers, pediatrics, biologics, labeling, life cycle management, guidance and policy implementation and development, and regulatory project management. Not all knowledge areas will be needed for every review.
· 审评组由 OCP 各单元人员组成,构成取决于本次审评所需的知识类型。这些领域可能包括药物与疾病相关的临床药理学、定量药理学、基因组学及其他生物标志物、儿科、生物制品、说明书、生命周期管理、指南与政策的实施和制定,以及监管项目管理。并非每次审评都需要全部知识领域。
OCP review team roles are listed below.
OCP 审评组的角色如下。
OCP Regulatory Project Manager
OCP 法规项目经理
OCP Regulatory Project Managers (OCP RPMs) are the regulatory experts for the application. They are responsible for notifying the relevant review divisions within OCP of new molecular entity NDA and original BLA submissions. OCP RPMs coordinate OCP reviewer assignments and communicate the assignments to the Office of New Drugs, Office of Regulatory Operations RPMs (OND/ORO RPMs). OCP RPMs will ensure that appropriate experts, including labeling, pediatrics, life cycle management, as well as experts in biologics programs, guidance, and policy are consulted as required. OCP RPMs are responsible for scheduling and managing the OCP scoping and briefing meetings, capturing minutes of the discussion, and archiving minutes in accordance with current Records Management practices. They provide reviewer tools, templates, and knowledge management, and they promote consistent communication throughout the review of the application.
OCP 法规项目经理(OCP RPM)是该申报的监管事务专家,负责就新分子实体 NDA 与原创 BLA 申报通知 OCP 内相关审评处。OCP RPM 协调 OCP 审评人员的分派,并将分派结果告知新药办公室与法规运营办公室的 RPM(OND/ORO RPM)。OCP RPM 应确保按需咨询相关专家,包括说明书、儿科、生命周期管理,以及生物制品项目、指南与政策方面的专家。OCP RPM 负责安排和管理 OCP 的范围界定会与简报会,记录讨论纪要,并按现行记录管理规范归档。他们提供审评工具、模板与知识管理支持,并在整个审评过程中推动沟通的一致性。
OCP Primary Reviewers
OCP 主审人
OCP primary reviewers are responsible for assessing information in the submission, analyzing and interpreting data, and completing individual study report reviews or integrated summaries of individual study reviews. The primary reviewers are responsible for authoring their respective parts of the integrated review and jointly communicating the overall OCP recommendations derived from the review. They will participate in internal FDA meetings, external meetings with applicants, and advisory committee meetings.
OCP 主审人负责评估申报资料中的信息、分析与解读数据,完成单项研究报告审评或单项研究审评的综合摘要。主审人负责撰写综合审评中各自的部分,并共同传达由审评得出的 OCP 总体建议。他们参加 FDA 内部会议、与申请人的外部会议以及顾问委员会会议。
OCP Lead Author of the Integrated Review
OCP 综合审评主笔
The OCP review team will identify the lead author based on the clinical pharmacology issues identified for the submission. The lead author is responsible for integrating information from primary reviews and leading the completion of the issue-based, interdisciplinary review with input from other OCP reviewers. The lead author is usually the lead reviewer representing the OCP team at the CDER multidisciplinary review team meetings. The lead author will also ensure accurate representation of all OCP knowledge areas in the OCP review team in reviews, presentations, and communications related to the application.
OCP 审评组根据本申报所识别的临床药理学问题确定主笔。主笔负责整合各主审审评中的信息,并在其他 OCP 审评人员参与下,牵头完成基于问题的跨学科综合审评。主笔通常即代表 OCP 审评组出席 CDER 多学科审评组会议的首席审评人。主笔还应确保在与本申报相关的审评、汇报与沟通中,准确体现 OCP 审评组覆盖的全部知识领域。
OCP Team Lead (TL) and/or Secondary Reviewer
OCP 团队负责人(TL)和/或复审人
The OCP TLs or secondary reviewers are responsible for conducting secondary review to provide scientific and regulatory advice and input to primary reviewers, having appropriate discussions of key review issues, ensuring that a high-quality review is completed within agreed-upon timelines, ensuring that the summary of OCP's findings and regulatory recommendations are comprehensive and clear, and communicating with relevant parties within and outside OCP.
OCP 团队负责人或复审人负责实施复审,向主审人提供科学与监管方面的意见与投入,就关键审评问题开展适当讨论,确保在约定时限内完成高质量审评,确保 OCP 发现与监管建议的总结全面、清晰,并与 OCP 内外相关方沟通。
OCP Application TL
OCP 申报团队负责人
The OCP application TL is responsible for leading the review and overseeing the integrated review process to ensure overall review efficiency, quality, and consistency. The TLs and/or secondary reviewers work with each other to identify the application TL.
OCP 申报团队负责人负责牵头审评并监督综合审评过程,以确保审评整体效率、质量与一致性。各团队负责人和/或复审人相互协商确定申报团队负责人。
OCP Application Signatory
OCP 申报签署人
An OCP Division Director or their designee serves as the final review signatory and is responsible for ensuring that the official OCP positions on review issues (e.g., approvability, dosage, labeling, PMRs and/or PMCs) are clearly stated. They are also responsible for ensuring reviews are comprehensive and clearly written. They promote consistency in the review, ensure transparency in the decision-making process, and guide review teams on complicated or precedent-setting review issues that may have policy implications. They interact with OCP senior management, the OCP Director, and other CDER staff to identify issues in a timely manner and resolve them as needed. They will author an OCP Application Signatory Memorandum when situations outlined in PROCEDURES (See bullet 7) occur.
OCP 某处处长或其指定人员担任最终审评签署人,负责确保 OCP 对审评问题(例如可否批准、剂量、说明书、PMR 和/或 PMC)的官方立场得到清晰表述;也负责确保审评全面、行文清晰。签署人推动审评的一致性,确保决策过程的透明度,并就复杂或有先例意义、可能涉及政策影响的审评问题指导审评组。他们与 OCP 高层、OCP 主任及其他 CDER 人员沟通,及时识别问题并按需解决。当出现“程序”第 7 条所述情形时,签署人应撰写 OCP 申报签署人备忘录。
PROCEDURES
程序
1. Reviewers in OCP will adhere to established goal dates.
1. OCP 审评人员应遵守既定的目标日期。
2. Review teams will follow the most recent and up-to-date OCP Internal Quality Procedures.
2. 审评组应遵循最新版本的 OCP 内部质量程序。
3. Regulatory project management staff or other members of the review team should schedule additional formal meetings as needed (e.g., pre-filing meetings to gain alignment on potential filing issues from OCP's perspective, pre-mid-cycle/pre-briefing meetings to discuss clinical pharmacology issues, content, and deliverables before presenting these findings outside OCP).
3. 法规项目管理人员或审评组其他成员应按需安排额外的正式会议,例如:受理前会议,就 OCP 视角下的潜在受理问题取得一致;中周期前/简报前会议,在向 OCP 之外呈报发现之前讨论临床药理学问题、内容与交付物。
4. Informal meetings and communication among OCP review team members and other discipline reviewers (e.g., clinical, biostatistics, pharmacology and toxicology, chemistry, manufacturing) are encouraged. Because participation in meetings is issue-based, keeping the entire OCP review team informed of key findings is important throughout the review process. Thus, important review findings that might influence approval or labeling decisions should be discussed among the OCP review team to gain alignment prior to engaging with other members of the CDER review team. Relevant outcomes of interactions with other disciplines outside of OCP that may be relevant to the OCP review should be shared with the rest of the OCP review team.
4. 鼓励 OCP 审评组成员与其他学科审评人员(如临床、生物统计、药理与毒理、化学、生产)之间进行非正式会议与沟通。由于会议参与是基于问题的,在整个审评过程中让 OCP 全组了解关键发现十分重要。因此,可能影响批准或说明书决定的重要审评发现,应在与 CDER 审评组其他成员接触之前,先在 OCP 审评组内讨论并取得一致。与 OCP 之外其他学科互动中可能对 OCP 审评相关的成果,应与 OCP 审评组其余成员共享。
5. Reviewers in OCP will follow the review principles outlined in the POLICY section when documenting their reviews.
5. OCP 审评人员在记录审评时,应遵循“政策”一节所列的审评原则。
6. Differences in opinions with respect to review and/or process will be resolved among the OCP review team members. For unresolved issues, Division leadership or the final OCP signatory will resolve the differences together with the review team and document the final decision in accordance with MAPP 4151.8 Rev.1.
6. 关于审评和/或流程的意见分歧,应在 OCP 审评组成员之间解决。对于未解决的问题,由处领导或 OCP 最终签署人与审评组共同解决分歧,并按 MAPP 4151.8 Rev.1 记录最终决定。
7. A separate OCP Application Signatory Memorandum will be written when there is major disagreement within the OCP review team that cannot be resolved during review, when the application signatory does not agree with the final recommendations of the review team, when OCP is taking a precedential or controversial review position, or when the complexity of the review issues necessitates further written communication.
7. 出现下列情形时,应单独撰写 OCP 申报签署人备忘录:OCP 审评组内部存在审评期间无法解决的重大分歧;申报签署人不同意审评组的最终建议;OCP 采取有先例意义或有争议的审评立场;或审评问题复杂、需要进一步书面沟通。
8. All communications with the sponsor will be made through the OND RPM. When questions to the applicant need to be sent in the form of an information request (IR), effort should be made to combine questions and input from all relevant OCP review disciplines.
8. 与申办方的所有沟通均通过 OND 的 RPM 进行。当需要以信息请求(IR)形式向申请人发问时,应尽量把 OCP 各相关审评学科的问题与意见合并提出。
REFERENCES
参考文献
1. CDER MAPP 4151.8 Rev.2, Equal Voice: Collaboration and Regulatory and Policy Decision-Making in CDER (2025).
1. CDER MAPP 4151.8 Rev.2《平等发言:CDER 内的协作与监管及政策决策》(2025年)。
EFFECTIVE DATE
生效日期
This MAPP is effective upon date of publication.
本 MAPP 自发布之日起生效。
CHANGE CONTROL TABLE
变更控制表
生效日期 | 修订号 | 修订内容 |
|---|---|---|
11/10/2026 | Initial | N/A |
原文表头为 Effective Date / Revision Number / Revisions,仅一行记录:2026年11月10日,Initial,N/A。
ATTACHMENT 1
附件1 OCP 的基于问题的审评:一般信息与模板
General Information
一般信息
The purpose of the review template is to consistently ensure that critical information is presented by OCP review teams in a prioritized, issue-driven, and logical manner. The template provides standardization and consistency in the format and content of clinical pharmacology reviews and ensures that critical presentations and analyses will not be inadvertently omitted. The standardized structure also enables readers to readily locate specific information. As such, headings and subheadings are named, numbered, and ordered as stipulated in the template unless there is a compelling reason not to for a specific application.
审评模板的目的,是持续确保 OCP 审评组以有优先级、以问题为驱动、合乎逻辑的方式呈现关键信息。模板使临床药理学审评的格式与内容标准化、一致化,并确保关键陈述与分析不会被无意遗漏;标准化的结构也使读者能迅速定位特定信息。因此,除非针对具体申报有充分理由不这样做,标题与子标题应按模板规定命名、编号并排序。
Information should generally not be repeated within the review. Reviewers may refer the reader to relevant sections and use hypertext links where appropriate. Text, tables, and figures may be used to summarize information, but redundancy should be avoided. The approach that best ensures clarity and understanding should be used. Proper attribution regarding data sources and analyses is expected. Reviews should be clear as to which assertions, conclusions, and recommendations are those of the applicant and those of the review team. Coherent and concise writing is expected for all draft and final reviews.
审评中一般不应重复信息。审评人员可引导读者参阅相关章节,并在适当处使用超链接。可用文字、表格与图归纳信息,但应避免冗余;应采用最能保证清晰与理解的方式。对数据来源与分析应有恰当的标注。审评应清楚区分哪些主张、结论与建议属于申请人、哪些属于审评组。所有草稿与终稿审评均应行文连贯、简洁。
The template may be modified by OCP review teams if deemed necessary to ensure clarity and cohesion for a given application; however, this scenario is expected to be a rare occurrence. The content of this template can easily be incorporated into other CDER integrated review team templates as appropriate.
如为确保具体申报的清晰与连贯确有必要,OCP 审评组可修改模板;但预期这种情况很少发生。本模板的内容可依适当情况,方便地并入 CDER 其他综合审评组的模板。
Review Structure
审评结构
The OCP integrated review consists of four sections. An overview of these four sections with a description of their target audiences is provided in Table 1.
OCP 综合审评由四个部分组成,四部分及其目标读者的概览见表 1。
· Section 1. Executive Summary: Summarizes OCP's position and final recommendations on key regulatory actions (e.g., approvability, dosing, labeling, need for PMR and/or PMC).
· 第 1 部分 执行摘要:概述 OCP 对关键监管行动(例如可否批准、给药、说明书、是否需要 PMR 和/或 PMC)的立场与最终建议。
· Section 2. Summary of Clinical Pharmacology Assessment: Summarizes major clinical pharmacology information and analyses used to address issue-specific review questions.
· 第 2 部分 临床药理学评价摘要:概述用于回答具体审评问题的主要临床药理学信息与分析。
· Section 3. Comprehensive Clinical Pharmacology Review: Contains more detailed information and explains the thought process for clinical pharmacology questions that are relevant to the application.
· 第 3 部分 临床药理学综合审评:包含更详细的信息,并阐述与本申报相关的临床药理学问题的思考过程。
· Section 4. Appendixes: Includes individual study report reviews or integrated summary of individual study reviews, and/or analyses on various clinical pharmacology areas that inform key regulatory actions.
· 第 4 部分 附录:包含单项研究报告审评或单项研究审评的综合摘要,和/或对为关键监管行动提供依据的各临床药理学领域的分析。
All four sections will be entered in the Center for Drug Evaluation and Research (CDER) review archival system as a complete clinical pharmacology review.
四个部分将作为一个完整的临床药理学审评,录入 CDER 的审评归档系统。
综合审评部分 | 内容 | 目标读者 |
|---|---|---|
Section 1 | 关键监管行动的立场与最终建议 | OCP、OND 及 CDER 高层 |
Section 2 | 回答具体审评问题的主要信息与分析 | OCP、OND 及 CDER 高层 |
Section 3 | 详细资料与思维过程 | OCP 人员与多学科审评组成员 |
Section 4 | 单项研究审评/综合摘要、各领域分析 | OCP 人员、多学科审评组成员、监管科学家 |
表 1 原文标题:Table 1. Overall Structure and Target Audience for Integrated Clinical Pharmacology Reviews。
OCP-Specific Issue-based Review Template
OCP 基于问题的审评模板(表头字段)
字段(原文) | 中文 |
|---|---|
NDA / BLA Number | NDA 或 BLA 编号 |
Link to EDR | 电子文档室(EDR)链接 |
Submission Date | 申报日期 |
Submission Type | 申报类型(注明优先审评或标准审评) |
Brand Name | 商品名 |
Established Name or Proper Name | 通用名或专有名 |
Dosage Form(s) and Strength(s) | 剂型与规格 |
Route(s) of Administration | 给药途径 |
Proposed Dosing | 拟用给药方案 |
Proposed Indication(s) | 拟定适应证 |
Applicant | 申请人 |
Associated INDs | 相关 IND(含与 MIDD 会议、EOP2、Pre-NDA 和/或儿科研究计划相关的 IND) |
OCP Review Team | OCP 审评组(主笔列首位) |
OCP Final Signatory | OCP 最终签署人(姓名与职务) |
脚注(原文):1 NDA: new drug application;2 BLA: biologics license application;3 EDR: electronic document room;4 IND: investigational new drug application;5 MIDD: model informed drug development;6 EOP2: end of phase 2。
Table of Contents
模板目录(四部分与子节)
编号 | 标题 |
|---|---|
1 | Executive Summary |
1.1 | Recommendations |
1.2 | Postmarketing Requirements and Commitments |
2 | Summary of Clinical Pharmacology Assessment |
2.1 | Pharmacology and Clinical Pharmacokinetics |
2.2 | Dosage and Therapeutic Individualization |
2.2.1 | General Dosage |
2.2.2 | Therapeutic Individualization |
2.3 | Outstanding Issues |
2.4 | Summary of Labeling Recommendations |
3 | Comprehensive Clinical Pharmacology Review |
3.1 | Overview of the Product and Regulatory Background |
3.2 | General Pharmacological and Pharmacokinetic Characteristics |
3.3 | Clinical Pharmacology Review Questions |
3.3.1 | To what extent does the available clinical pharmacology information provide evidence of effectiveness? |
3.3.2 | Is the proposed dosage appropriate for the general patient population for which the indication is being sought? |
3.3.3 | Is an alternative dosage and/or management strategy required for subpopulations based on intrinsic factors? |
3.3.4 | Are there clinically relevant food-drug or drug-drug interactions, and what is the appropriate management strategy? |
4 | Appendixes |
1 Executive Summary
第 1 部分 执行摘要
The executive summary: (1) very briefly highlights the drug development program, intended place in therapy, or other relevant background information; (2) notes any novel, precedential, or controversial issues and how they were addressed; (3) highlight major review issues addressed; and (4) provides the positions/recommendations of the OCP review team.
执行摘要应:(1) 极为简要地概述药物开发项目、拟定的治疗地位或其他相关背景信息;(2) 指出任何新颖的、有先例意义的或有争议的问题,以及这些问题是如何处理的;(3) 突出已处理的主要审评问题;(4) 给出 OCP 审评组的立场/建议。
1.1 Recommendations
1.1 建议
The recommendations section is intended for the communication of OCPs positions and recommendations for regulatory action and key review questions as outlined below:
“建议”一节用于传达 OCP 对监管行动与关键审评问题的立场和建议,具体如下:
· The OCP review team will explicitly state OCP's position on approvability and the following key issues as appropriate: adequacy of dosage information, adequacy of risk management (if necessary), and adequacy of labeling and health communication.
· OCP 审评组应明确表述 OCP 对可否批准的立场,并按适当情况表述对以下关键问题的立场:剂量信息是否充分、风险管理是否充分(如有必要)、说明书与健康传播是否充分。
· The OCP review team will recommend a complete response (CR) if there are major clinical pharmacology deficiencies that preclude safe and effective use and cannot be addressed by labeling, risk management options beyond labeling, or by conducting postmarketing studies.
· 若存在重大临床药理学缺陷,导致无法安全有效使用,且不能通过说明书、说明书之外的风险管理措施或开展上市后研究加以解决,OCP 审评组应建议发出完整回复(CR)。
· The OCP review team will use the table below to summarize OCP's recommendations and comments on key review issues.
· OCP 审评组应使用下表概述 OCP 对关键审评问题的建议与意见。
审评问题(原文) | 中文 | 建议与意见 |
|---|---|---|
Evidence of effectiveness | 有效性证据 | |
General dosage instructions | 通用剂量说明 | |
Dosing in patient subgroups (intrinsic and extrinsic factors) | 患者亚组给药(内在与外在因素) | |
Labeling | 说明书 | |
Bridge between the to-be-marketed and clinical trial formulations | 拟上市制剂与临床试验制剂的桥接 | |
Other (specify) | 其他(具体说明) |
原文脚注:1 Refer to 21 CFR 320.21。原表“建议与意见”列为空白,供审评时填写。
1.2 Postmarketing Requirements and Commitments
1.2 上市后要求与承诺
If there is no need for a PMR or PMC, state that in this section. Otherwise, describe the need for establishing PMRs and PMCs. Describe the issues to be addressed, the justification for the PMR and/or PMC, and the experimental/methodological approaches recommended using the table below (repeat rows as needed).
若不需要 PMR 或 PMC,应在本节中说明。否则,应描述设立 PMR 与 PMC 的必要性,说明拟解决的问题、PMR 和/或 PMC 的理由,以及建议的实验/方法学路径,使用下表(按需重复行)。
列(原文) | 中文 | 填写要求 |
|---|---|---|
PMC or PMR | 上市后承诺 / 上市后要求 | 标明类型 |
Key Issue(s) to be Addressed | 拟解决的关键问题 | 一句话说清问题 |
Rationale | 理由 | 为何必须上市后解决 |
Key Considerations for Design Features | 设计要素的关键考虑 | 人群、终点、样本量、时限等 |
原表为空白模板,四列依次为 PMC or PMR / Key Issue(s) to be Addressed / Rationale / Key Considerations for Design Features。
2 Summary of Clinical Pharmacology Assessment
第 2 部分 临床药理学评价摘要
This section provides an integrated synopsis of the major clinical pharmacology issues dealt with in the course of a typical OCP review of an NDA, BLA, or OMOR. Only topline information should be presented in this section. Additional details are expected to be included in the section 3 Comprehensive Clinical Pharmacology Review.
本节对 NDA、BLA 或 OMOR(OTC 专论令申请)的常规 OCP 审评中所处理的主要临床药理学问题作综合概述。本节只呈现主线信息,更多细节应放在第 3 部分“临床药理学综合审评”中。
The information in this section is organized into subsections 2.1 to 2.4 to address the following topics:
本节信息按 2.1 至 2.4 各子节组织,涵盖以下主题:
· Brief description of findings and conclusions in support of OCP recommendations
· 支持 OCP 建议的发现与结论的简要描述。
· Appropriateness of proposed dosage for the indication(s) sought
· 拟用剂量对申请适应证的适当性。
· Appropriateness of dosage and/or treatment in relevant patient subsets (e.g., molecularly defined, segmented by degrees of organ impairment)
· 相关患者亚组(例如按分子特征定义、按器官损伤程度划分)中剂量和/或治疗的适当性。
· Presence or likelihood of clinically significant food-drug or drug-drug interactions and their clinical management strategies
· 是否存在或有较大可能存在有临床意义的食物-药物或药物-药物相互作用及其临床管理策略。
· Other clinical pharmacology issues (e.g., available strengths, bridging of to-be-marketed formulations to clinical experience) relevant to the optimal use of the drug in populations or individuals
· 与药品在人群或个体中优化使用相关的其他临床药理学问题(例如可及规格、拟上市制剂与临床经验的桥接)。
· Areas of uncertainty in the review (e.g., where assumptions were critical in filling information gaps)
· 审评中的不确定之处(例如在填补信息缺口时哪些假设起关键作用)。
· Important omissions from the application
· 申报资料中的重要遗漏。
· High-level labeling recommendations
· 概要性说明书建议。
Subsections 2.1 to 2.4 are described below.
2.1 至 2.4 各子节的要求如下。
2.1 Pharmacology and Clinical Pharmacokinetics
2.1 药理学与临床药代动力学
Provide topline information on the pharmacologic and pharmacokinetic (e.g., absorption, distribution, metabolism, and excretion) properties of the drug.
提供该药药理学与药代动力学(例如吸收、分布、代谢与排泄)特征的主线信息。
A detailed description is not necessary for clinical pharmacokinetic studies (e.g., single and multiple ascending doses, specific populations, drug interactions, relative bioavailability, and other studies).
对临床药代动力学研究(例如单次与多次剂量递增、特定人群、药物相互作用、相对生物利用度等研究),不必作详细描述。
2.2 Dosage and Therapeutic Individualization
2.2 剂量与治疗个体化
2.2.1 General Dosage
2.2.1 通用剂量
Summarize the assessment and final recommended dosage recommendations for the general patient population for which the indication(s) are being sought. This includes a synopsis of the dosage finding strategy, how it led to the recommended dosage, and the reviewer's assessment on the adequacy of the dosage.
概述对申请适应证所针对的通用患者人群的评价与最终推荐剂量,包括剂量探索策略的概要、该策略如何得出推荐剂量,以及审评人对剂量是否充分的评价。
2.2.2 Therapeutic Individualization
2.2.2 治疗个体化
Summarize the assessment and final recommendations on the dosage and/or the appropriateness of treatment in relevant patient subsets based on various intrinsic (e.g., organ impairment, genotype) or extrinsic (e.g., food, drug interactions) factors.
概述基于各种内在因素(例如器官损伤、基因型)或外在因素(例如食物、药物相互作用),对相关患者亚组剂量和/或治疗适当性的评价与最终建议。
2.3 Outstanding Issues
2.3 未决问题
Describe areas of uncertainty in the review and important omissions from the application. Describe high-level recommendations on preferred approaches to resolving these outstanding issues (e.g., PMR and PMC). Also note if the submission did not adequately address important biopharmaceutics and bioanalytical issues. State “None” if there are no outstanding issues.
描述审评中的不确定之处与申报资料中的重要遗漏,并就解决这些未决问题的首选路径(例如 PMR 与 PMC)给出概要建议。还应说明申报是否未能充分解决重要的生物药剂学与生物分析问题。若无未决问题,应写明“None(无)”。
2.4 Summary of Labeling Recommendations
2.4 说明书建议摘要
Describe labeling recommendations at a high level, including areas of concurrence/disagreement. The information is captured in a narrative description of the labeling issues. Extensive redline/strike outs of the applicant's proposed labeling are generally not be included.
概要描述说明书建议,包括意见一致/不一致之处。相关信息以对说明书问题的叙述性描述呈现;一般不包括对申请人拟定说明书的大段修订标记(redline)或删除线。
3 Comprehensive Clinical Pharmacology Review
第 3 部分 临床药理学综合审评
In subsequent subsections, integrate information across studies to address review questions that are most relevant to the application. Organize information under broad categories of questions in this section where appropriate.
在后续各子节中,跨研究整合信息,以回答与本申报最相关的审评问题。适当时,将信息按问题的大类组织。
State the answer to key review questions up front and provide details to support the conclusion. Regulatory recommendations, including the rationale for particular labeling recommendations, are clearly stated in the appropriate section.
应先给出关键审评问题的答案,再提供支持结论的细节。监管建议——包括特定说明书建议的理由——应在相应章节中清楚表述。
3.1 Overview of the Product and Regulatory Background
3.1 产品与监管背景概述
Only relevant product information and regulatory history/activities (including key milestone discussions) that contribute to the clinical pharmacology assessment are described.
仅描述对临床药理学评价有贡献的相关产品信息与监管历史/活动(包括关键里程碑讨论)。
3.2 General Pharmacology and Pharmacokinetic Characteristics
3.2 一般药理与药代特征
Include a general overview of the drug's non-clinical and clinical pharmacology information to provide a context for specific OCP recommendations. Briefly include information on the drug substance (note for BLAs, drug or drug substance means the therapeutic protein, terms which can be used interchangeably), drug product, and bioanalytical method if relevant to an important aspect of the review. Key information may be summarized in a table format.
概述该药的非临床与临床药理学信息,为 OCP 的具体建议提供背景。简要纳入原料药(注意:对 BLA 而言,drug 或 drug substance 指治疗性蛋白,两个术语可互换使用)、制剂与生物分析方法的资料——以与审评重要方面相关为限。关键信息可用表格归纳。
3.3 Clinical Pharmacology Review Questions
3.3 临床药理学审评问题
This section addresses a series of clinical pharmacology questions that are relevant to the safe and effective use of all drugs. These questions should be answered explicitly and up front.
本节处理一系列与所有药品安全有效使用相关的临床药理学问题。这些问题应在开篇明确回答。
3.3.1 Do the available clinical pharmacology data contribute to the evidence of effectiveness?
3.3.1 现有临床药理学数据是否构成有效性证据?
Clinical pharmacology information often provides substantial evidence of effectiveness in situations that involve extrapolation of findings of an approved product to a new population (e.g., adults to pediatric patients), a different dose, dosing regimen, or dosage form. In other situations, clinical pharmacology data may be considered confirmatory evidence of effectiveness or may otherwise contribute to the body of data providing substantial evidence of effectiveness. For more information, see the guidance for industry Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products (May 1998).2 See also the draft guidances Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products (December 2019) and Demonstrating Substantial Evidence of Effectiveness Based on One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence (September 2023).3
在需要将已获批产品的研究结果外推到新人群(例如成人外推到儿科患者)、不同剂量、不同给药方案或不同剂型的场景中,临床药理学信息常常构成实质性的有效性证据。在其他情况下,临床药理学数据可被视为有效性的确证性证据,或以其他方式充实构成实质性有效性证据的数据体。更多信息见行业指南《人用药品与生物制品有效性的临床证据》(1998年5月);另见两份指南草案《证明人用药品与生物制品的实质性有效性》(2019年12月)与《基于一项充分且良好对照的临床研究和确证性证据证明实质性有效性》(2023年9月)。
In general, a recap of efficacy results is not warranted, except in situations in which compelling clinical pharmacology information can be used to provide additional evidence of effectiveness for an NDA or BLA. Situations where the available clinical pharmacology data contribute to the evidence of effectiveness include, but may not be limited to:
一般而言,不必复述有效性结果——除非有强有力的临床药理学信息可用于为 NDA 或 BLA 提供额外的有效性证据。现有临床药理学数据构成有效性证据的情形包括但不限于:
· Providing mechanistic evidence of a drug's treatment effect that may be appropriate to be considered as confirmatory evidence to a single adequate and well-controlled trial (e.g., because of an effect on a relevant pharmacodynamic biomarker).
· 提供药物疗效的作用机制证据,可用作单项充分且良好对照试验的确证性证据(例如基于对相关药效学生物标志物的影响)。
· Identifying subsets of patients with notably large treatment effects or favorable risk/benefit balance for a drug with significant toxicity or otherwise marginal average treatment effects.
· 识别治疗效应显著更大、或获益/风险平衡更有利的患者亚组——这对毒性显著或平均疗效处于边缘的药物尤其有意义。
· Contributing to evaluation of a biomarker as a fully validated surrogate or one reasonably likely to predict clinical benefit.
· 为将某一生物标志物评价为完全验证的替代终点、或有可能预测临床获益的替代终点提供依据。
· Providing exposure-response information contributing to the understanding of drug effect in the intended population.
· 提供暴露-效应信息,有助于理解药物在目标人群中的作用。
· Determining the individual contributions of components of a combination therapy (e.g., in the absence of a full factorial clinical trial).
· 确定联合治疗各组分各自的贡献(例如在缺乏全因子临床试验的情况下)。
In general, safety of the drug should be discussed in section 3.3.2 as part of the risk-benefit assessment of the proposed dosing regimen for the general population. However, in rare instances, if there is a mechanistic basis for a significant safety concern that may outweigh the benefit of the drug's intended pharmacologic effect, it may be appropriate to include a brief statement of the risk in this section to provide proper context.
一般而言,药物安全性应在 3.3.2 节中,作为通用人群拟用给药方案获益-风险评估的一部分讨论。但在少数情况下,若某重大安全性担忧有机制层面的依据、且可能超过药物预期药理作用带来的获益,则宜在本节简要说明该风险,以提供恰当的背景。
3.3.2 Is the proposed dosage appropriate for the general patient population for which the indication is being sought?
3.3.2 拟用剂量对申请适应证所针对的通用患者人群是否合适?
Provide an assessment of and final dosage recommendations for the general patient population for which the indication is being sought. This section could also include the details on the dose finding approach as well as the integrative approach taken (including pharmacokinetic, pharmacodynamic, efficacy, and safety information) to support the proposed dosing regimen. If necessary, this section should include revised dosing recommendations to be incorporated into labeling or proposal for further studies to resolve any unresolved issues related to dosing for the indication sought.
对申请适应证所针对的通用患者人群给出评价与最终剂量建议。本节还可包含剂量探索方法的细节,以及为支持拟用给药方案所采取的综合方法(含药代、药效、有效性与安全性信息)。如有必要,本节应给出拟纳入说明书的修订剂量建议,或提出进一步研究方案,以解决与申报适应证给药相关的未决问题。
Information needed to address this question may include (but is not limited to):
回答本问题所需的信息可能包括(但不限于):
· Dose-exposure-response analyses for drug activity, safety and/or efficacy, where available
· 药物活性、安全性和/或有效性的剂量-暴露-效应分析(如有)。
· Therapeutic index of the drug if known
· 该药的治疗指数(如已知)。
· Applicant's rationale to support dosing or labeling claims
· 申请人支持给药或说明书主张的理由。
· Additional analyses if OCP's conclusion is different from that of the applicant
· 若 OCP 结论与申请人不同,需补充的分析。
3.3.3 Is an alternative dosing regimen and/or management strategy required for subpopulations based on intrinsic factors?
3.3.3 基于内在因素,亚人群是否需要替代给药方案和/或管理策略?
Provide an assessment of and final recommendations on dosage and/or the appropriateness of treatment in relevant patient subsets based on various intrinsic factors. Intrinsic factors include age, sex, race/ethnicity, genetics, body weight, organ impairment, etc.
基于各种内在因素,对相关患者亚组的剂量和/或治疗适当性给出评价与最终建议。内在因素包括年龄、性别、种族/民族、遗传、体重、器官损伤等。
If necessary, this section should include revised dosage recommendations to be incorporated into labeling or proposals for further studies to resolve any unresolved issues related to dosage in specific populations. The basis for alternative dosage recommendations in these populations should be explicitly described (e.g., average exposure matching, interpolation or extrapolation based on exposure-response analyses).
如有必要,本节应给出拟纳入说明书的修订剂量建议,或提出进一步研究方案,以解决特定人群中与给药相关的未决问题。这些人群采用替代剂量的依据应明确描述(例如平均暴露匹配、基于暴露-效应分析的插值或外推)。
This section can provide information on:
本节可提供以下信息:
· Intrinsic factors that influence exposure (pharmacokinetics of parent and/or relevant metabolites) and/or pharmacodynamics of the drug.
· 影响暴露(原形药物和/或相关代谢物的药代动力学)和/或药效学的内在因素。
· Whether a dosage adjustment is warranted for a particular subpopulation and the nature of the data that support those conclusions.
· 某一亚人群是否需要调整剂量,以及支持该结论的数据性质。
· Applicant-proposed management strategies (if any).
· 申请人提出的管理策略(如有)。
· Review team-proposed management strategies (if different from the applicant).
· 审评组提出的管理策略(如与申请人不同)。
· Rationale to support proposed management strategies (e.g., based on empirical results from dedicated standalone or nested studies, modeling, simulation, theoretical concerns).
· 支持拟议管理策略的理由(例如基于专门单独研究或嵌套研究的实证结果、建模、模拟、理论上的担忧)。
· Whether intrinsic factors were adequately assessed and if such information is pertinent to safe and effective use of the drug.
· 内在因素是否得到充分评估,以及这些信息是否与药物安全有效使用相关。
· Intrinsic factors that were evaluated or considered but that do not influence exposure should be discussed. The adequacy of the data to support a negative finding should be discussed.
· 已评估或考虑但不影响暴露的内在因素也应讨论;并应讨论支持“无影响”这一阴性结论的数据是否充分。
3.3.4 Are there clinically relevant food-drug or drug-drug interactions, and what is the appropriate management strategy?
3.3.4 是否存在有临床意义的食物-药物或药物-药物相互作用?适当的管理策略是什么?
Provide assessment of and final recommendations on dosage and/or therapeutic management strategies needed to address important food-drug (including beverage-drug) or drug-drug interactions. If necessary, this section includes revised management strategies to be incorporated into the labeling or proposals for further studies to resolve such clinically relevant interactions. The basis for alternative dosages under these conditions is explicitly described (e.g., average exposure matching, interpolation or extrapolation based on exposure/response analyses).
对处理重要食物-药物(含饮料-药物)或药物-药物相互作用所需的剂量和/或治疗管理策略,给出评价与最终建议。如有必要,本节应包括拟纳入说明书的修订管理策略,或提出进一步研究方案以解决此类有临床意义的相互作用。这些情形下采用替代剂量的依据应明确描述(例如平均暴露匹配、基于暴露/效应分析的插值或外推)。
This section provides information on:
本节提供以下信息:
· The influence of food/diet, alcohol use, herbal supplements, and concomitant drugs on the exposure (pharmacokinetics of parent and/or relevant metabolites) and/or pharmacodynamics of the new drug.
· 食物/饮食、饮酒、草药补充剂与合并用药对新药暴露(原形药物和/或相关代谢物的药代动力学)和/或药效学的影响。
· The new drug's effect on the exposure and/or pharmacodynamics of concomitant drugs.
· 新药对合并用药暴露和/或药效学的影响。
· Whether a dosage adjustment is warranted and the nature of the data that supports those conclusions.
· 是否需要调整剂量,以及支持该结论的数据性质。
· Applicant-proposed management strategies (if any).
· 申请人提出的管理策略(如有)。
· Review team-proposed management strategies (if different from the applicant).
· 审评组提出的管理策略(如与申请人不同)。
· Rationale to support proposed management strategies (e.g., based on empirical results from dedicated standalone or nested studies, modeling, simulation, or theoretical concerns).
· 支持拟议管理策略的理由(例如基于专门单独研究或嵌套研究的实证结果、建模、模拟或理论上的担忧)。
· Whether the impact of food/diet, alcohol use, and drug-drug interactions were adequately assessed and if such information is pertinent to safe and effective use of the drug.
· 食物/饮食、饮酒及药物-药物相互作用的影响是否得到充分评估,以及这些信息是否与药物安全有效使用相关。
· Interactions that were evaluated or considered but that do not influence exposure should also be discussed. The adequacy of the data to support a negative finding needs to be discussed.
· 已评估或考虑但不影响暴露的相互作用也应讨论;并需讨论支持“无影响”这一阴性结论的数据是否充分。
4 Appendixes
第 4 部分 附录
This section is organized to include key individual study report reviews or integrated summaries of individual study reviews and analyses on various clinical pharmacology areas that inform major decisions and recommendations. Subsections should be divided into informative topical subheaders.
本部分的组织方式,是纳入关键的单项研究报告审评或单项研究审评的综合摘要,以及为重大决定与建议提供依据的各临床药理学领域分析。子节应按有信息量的专题子标题划分。
Reviewers should take into account whether pivotal clinical pharmacology studies are fit for their intended purposes based on study design, data quality, and the appropriateness of the data analysis. Reviews may include independent OCP data analyses. This section, as with other sections of the review, should not include non-essential information. The review team should exercise judgment on the breadth and depth of information to be included in this section.
审评人员应基于研究设计、数据质量以及数据分析的适当性,判断关键临床药理学研究是否适合其预期用途。审评可包含 OCP 的独立数据分析。本节与审评其他部分一样,不应纳入非必要信息;审评组应对本节所纳信息的广度与深度作出判断。
Examples of subheaders for this section are provided below:
本节的子标题示例见下:
4.1 Summary of Bioanalytical Method Validation and Performance
4.1 生物分析方法验证与性能摘要
4.2 Clinical PK and/or PD Assessments
4.2 临床药代和/或药效评价
4.3 Population PK and/or PD Analyses
4.3 群体药代和/或药效分析
4.4 Exposure-Response Analyses
4.4 暴露-反应分析
4.5 Enrichment, Stratification, and/or Biomarker-Based Assessment
4.5 富集、分层和/或基于生物标志物的评价
4.6 Mechanistic Safety Assessment
4.6 机制性安全性评价
来源:制药经理人 · mp.weixin.qq.com